Isoform-specific Effects of Neuronal Inhibition of AMPK Catalytic Subunit on LTD Impairments in a Mouse Model of Alzheimer's Disease

Overview

Journal Neurobiol Aging

Publisher Elsevier

Specialties Geriatrics
Neurology
Physiology

Date 2024 May 19

PMID 38763076

Authors

Qian Yang

Xueyan Zhou

Tao Ma

Affiliations

Soon will be listed here.

Abstract

Synaptic dysfunction is highly correlated with cognitive impairments in Alzheimer's disease (AD), the most common dementia syndrome in the elderly. Long-term potentiation (LTP) and long-term depression (LTD) are two primary forms of synaptic plasticity with opposite direction of synaptic efficiency change. Both LTD and LTD are considered to mediate the cellular process of learning and memory. Substantial studies demonstrate AD-associated deficiency of both LTP and LTD. Meanwhile, the molecular signaling mechanisms underlying impairment of synaptic plasticity, particularly LTD, are poorly understood. By taking advantage of the novel transgenic mouse models recently developed in our lab, here we aimed to investigate the roles of AMP-activated protein kinase (AMPK), a central molecular senor that plays a critical role in maintaining cellular energy homeostasis, in regulation of LTD phenotypes in AD. We found that brain-specific suppression of the AMPKα1 isoform (but not AMPKα2 isoform) was able to alleviate mGluR-LTD deficits in APP/PS1 AD mouse model. Moreover, suppression of either AMPKα isoform failed to alleviate AD-related NMDAR-dependent LTD deficits. Taken together with our recent studies on roles of AMPK signaling in AD pathophysiology, the data indicate isoform-specific roles of AMPK in mediating AD-associated synaptic and cognitive impairments.

References

Zimmermann H, Yang W, Kasica N, Zhou X, Wang X, Beckelman B . Brain-specific repression of AMPKα1 alleviates pathophysiology in Alzheimer's model mice. J Clin Invest. 2020; 130(7):3511-3527. PMC: 7324210. DOI: 10.1172/JCI133982. View

Cooke S, Bliss T . Plasticity in the human central nervous system. Brain. 2006; 129(Pt 7):1659-73. DOI: 10.1093/brain/awl082. View

Grahame Hardie D . AMPK--sensing energy while talking to other signaling pathways. Cell Metab. 2014; 20(6):939-52. PMC: 5693325. DOI: 10.1016/j.cmet.2014.09.013. View

Roberson E, Mucke L . 100 years and counting: prospects for defeating Alzheimer's disease. Science. 2006; 314(5800):781-4. PMC: 3544944. DOI: 10.1126/science.1132813. View

Moreno J, Radford H, Peretti D, Steinert J, Verity N, Martin M . Sustained translational repression by eIF2α-P mediates prion neurodegeneration. Nature. 2012; 485(7399):507-11. PMC: 3378208. DOI: 10.1038/nature11058. View

Klann E, Dever T . Biochemical mechanisms for translational regulation in synaptic plasticity. Nat Rev Neurosci. 2004; 5(12):931-42. DOI: 10.1038/nrn1557. View

Yang W, Zhou X, Zimmermann H, Cavener D, Klann E, Ma T . Repression of the eIF2α kinase PERK alleviates mGluR-LTD impairments in a mouse model of Alzheimer's disease. Neurobiol Aging. 2016; 41:19-24. PMC: 4841914. DOI: 10.1016/j.neurobiolaging.2016.02.005. View

Jankowsky J, Slunt H, Ratovitski T, Jenkins N, Copeland N, Borchelt D . Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 2001; 17(6):157-65. DOI: 10.1016/s1389-0344(01)00067-3. View

Grahame Hardie D, Ross F, Hawley S . AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012; 13(4):251-62. PMC: 5726489. DOI: 10.1038/nrm3311. View

10.

Kasica N, Zhou X, Yang Q, Wang X, Yang W, Zimmermann H . Antagonists targeting eEF2 kinase rescue multiple aspects of pathophysiology in Alzheimer's disease model mice. J Neurochem. 2021; 160(5):524-539. PMC: 8902702. DOI: 10.1111/jnc.15562. View

11.

Um J, Kaufman A, Kostylev M, Heiss J, Stagi M, Takahashi H . Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron. 2013; 79(5):887-902. PMC: 3768018. DOI: 10.1016/j.neuron.2013.06.036. View

12.

Ribeiro F, Vieira L, Pires R, Olmo R, Ferguson S . Metabotropic glutamate receptors and neurodegenerative diseases. Pharmacol Res. 2016; 115:179-191. DOI: 10.1016/j.phrs.2016.11.013. View

13.

Yang W, Zhou X, Zimmermann H, Ma T . Brain-specific suppression of AMPKα2 isoform impairs cognition and hippocampal LTP by PERK-mediated eIF2α phosphorylation. Mol Psychiatry. 2020; 26(6):1880-1897. PMC: 8054310. DOI: 10.1038/s41380-020-0739-z. View

14.

Huber K, Gallagher S, Warren S, Bear M . Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A. 2002; 99(11):7746-50. PMC: 124340. DOI: 10.1073/pnas.122205699. View

15.

Malenka R, Bear M . LTP and LTD: an embarrassment of riches. Neuron. 2004; 44(1):5-21. DOI: 10.1016/j.neuron.2004.09.012. View

16.

Selkoe D . Alzheimer's disease is a synaptic failure. Science. 2002; 298(5594):789-91. DOI: 10.1126/science.1074069. View

17.

Holtzman D, Mandelkow E, Selkoe D . Alzheimer disease in 2020. Cold Spring Harb Perspect Med. 2012; 2(11). PMC: 3543098. DOI: 10.1101/cshperspect.a011585. View

18.

Wang X, Zimmermann H, Lockhart S, Craft S, Ma T . Decreased Levels of Blood AMPKα1 but not AMPKα2 Isoform in Patients with Mild Cognitive Impairment and Alzheimer's Disease: A Pilot Study. J Alzheimers Dis. 2020; 76(1):217-224. PMC: 8009325. DOI: 10.3233/JAD-191189. View

19.

Steinberg G, Kemp B . AMPK in Health and Disease. Physiol Rev. 2009; 89(3):1025-78. DOI: 10.1152/physrev.00011.2008. View

20.

Bhattacharya A, Kaphzan H, Alvarez-Dieppa A, Murphy J, Pierre P, Klann E . Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron. 2012; 76(2):325-37. PMC: 3479445. DOI: 10.1016/j.neuron.2012.07.022. View